Viral Vector Manufacturing Market Worth $815.8 Million by 2023

PUNE, India, August 2, 2018 /PRNewswire/ --

According to a new market research report "Viral Vector Manufacturing Market by Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecast to 2023", published by MarketsandMarkets™, the market is expected to reach USD 815.8 million by 2023 from an estimated USD 327.8 million in 2018, at a CAGR of 20.0%.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Browse 50 market data Tables and 22 Figures spread through 107 Pages and in-depth TOC on "Viral Vector Manufacturing Market"

https://www.marketsandmarkets.com/Market-Reports/viral-vector-manufacturing-market-89341986.html

Early buyers will receive 10% customization on this report

The key factors driving the growth of this market include rising prevalence of cancer and genetic disorders, funding for the development of novel therapies, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene and cell therapies.

"The retroviral vectors segment is expected to account for the largest share of the Viral Vector Manufacturing Market by type in 2018" 

On the basis of type, the Viral Vector Manufacturing Market is segmented into retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors. Retroviral vectors are expected to hold the largest share in this market in 2018. The large share of these vectors can be attributed to their ease of application in major target diseases such as cancer, and genetic disorders.

"The genetic disorders segment is expected to grow at the highest CAGR during the forecast period" 

Based on diseases, the global Viral Vector Manufacturing Market is segmented into cancer, genetic disorders, infectious diseases, and other diseases. During the forecast period, the genetic disorders segment is expected to grow at the highest CAGR in the market. The accelerated research activities on various genetic disorders such as hemophilia A and B, sickle cell anemia, and Huntington's disease and a robust gene therapy pipeline in the last phase of drug development is fueling the growth of this segment.

The gene therapy segment is expected to account for the largest share of Viral Vector Manufacturing Market in 2018" 

Based on application, the global Viral Vector Manufacturing Market is segmented into gene therapy and vaccinology. In 2018, the gene therapy segment is expected to hold the largest share in this market and this segment is also expected to grow at the highest rate during the forecast period. The large share and fast growth of this segment can be attributed to the large number of clinical trials conducted for gene therapy on target diseases such as cancer, neurodegenerative diseases, and cardiovascular diseases globally.

Ask for PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=89341986

"North America is expected to dominate the Viral Vector Manufacturing Market in 2018" 

In 2018, North America is estimated to account for the largest share of the Viral Vector Manufacturing Market. Factors such as a large number of regenerative medicine companies (including gene and cell therapy companies), increasing research activities, rising prevalence of target diseases, and availability of funds are supporting the growth of the Viral Vector Manufacturing Market in North America.

The major players in the global Viral Vector Manufacturing Market are Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), Kaneka Eurogentec (Japan), and Spark Therapeutics (US).

Know more about the Viral Vector Manufacturing Market: 

https://www.marketsandmarkets.com/Market-Reports/viral-vector-manufacturing-market-89341986.html

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441

Email: [email protected]

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/viral-vector-manufacturing-market.asp

Connect with us on LinkedIn: http://www.linkedin.com/company/marketsandmarkets

SOURCE MarketsandMarkets